The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis
- Conditions
- DepressionMultiple Sclerosis
- Registration Number
- NCT00151294
- Lead Sponsor
- Weill Medical College of Cornell University
- Brief Summary
Emotionally labile, depressed participants with multiple sclerosis treated with escitalopram will have a greater reduction in emotional lability scores and in their psychological distress scores than those who are randomized to receive placebo.
- Detailed Description
Patients with multiple sclerosis who are experiencing mood lability and symptoms of depression will be randomized to receive either escitalopram 10mg/day or placebo tablets for a period of 6 weeks. It is hypothesized that patients receiving medication will experience a greater normalization of their emotional instability and a greater reduction in their depressive symptoms at the end of the six-week trial than those who are not receiving medication.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 20
- Clinical diagnosis of multiple sclerosis
- Having mild to moderate depressive symptoms, with or without emotional lability
- Experiencing psychological distress
- Meeting DSM-IV diagnostic criteria for Major Depressive Disorder or another Axis 1 diagnosis
- Cognitive impairment
- The presence of an unstable medical illness that might preclude completion of the study -
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Escitalopram-treated MS patients will have greater reductions in their depressive symptom scores than patients randomized to placebo Adverse events for both groups will be similar
- Secondary Outcome Measures
Name Time Method Escitalopram-treated emotionally labile patients with MS will have a greater reduction in emotional lability scores than those randomized to placebo.
Trial Locations
- Locations (1)
NewYork Presbyterian Hospital
🇺🇸White Plains, New York, United States